An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients With Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer

Trial Profile

An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients With Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 May 2014

At a glance

  • Drugs Mipsagargin (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Inspyr Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Feb 2014 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 06 Feb 2013 Planned End Date changed from 1 Oct 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top